Cost–utility analysis of liraglutide compared with sulphonylurea or sitagliptin, all as add‐on to metformin monotherapy in Type 2 diabetes mellitus
Authors:
Open Access
- 22 February 2012
- journal article
- research article
- Published by Wiley in Diabetic Medicine
- Vol. 29 (3) , 313-320
Abstract
Aim To investigate the cost-effectiveness of liraglutide as add-on to metformin vs. glimepiride or sitagliptin in patients with Type 2 diabetes uncontrolled with first-line metformin. Methods Data were sourced from a clinical trial comparing liraglutide vs. glimepiride, both in combination with metformin, and a clinical trial comparing liraglutide vs. sitagliptin, both as add-on to metformin. Only the subgroup of patients in whom liraglutide was added to metformin monotherapy was included in the costutility analysis. The CORE Diabetes Model was used to simulate outcomes and costs with liraglutide 1.2 and 1.8 mg vs. glimepiride and vs. sitagliptin over patients lifetimes. Treatment effects were taken directly from the trials. Costs and outcomes were discounted at 3.5% per annum and costs were accounted from a third-party payer (UK National Health System) perspective. Results Treatment with liraglutide 1.2 and 1.8 mg resulted, respectively, in mean increases in quality-adjusted life expectancy of 0.32 +/- 0.15 and 0.28 +/- 0.14 quality-adjusted life years vs. glimepiride, and 0.19 +/- 0.15 and 0.31 +/- 0.15 quality-adjusted life years vs. sitagliptin, and was associated with higher costs of 3003 pound +/- 678 pound and 4688 pound +/- 639 pound vs. glimepiride, and 1842 pound +/- 751 pound and 3224 pound +/- 683 pound vs. sitagliptin, over a patients lifetime. Both liraglutide doses were cost-effective, with incremental cost-effectiveness ratios of 9449 pound and 16 pound 501 per quality-adjusted life year gained vs. glimepiride, and 9851 pound and 10 pound 465 per quality-adjusted life year gained vs. sitagliptin, respectively. Conclusions Liraglutide, added to metformin monotherapy, is a cost-effective option for the treatment of Type 2 diabetes in a UK setting.Keywords
This publication has 15 references indexed in Scilit:
- Delivering the diabetes education and self management for ongoing and newly diagnosed (DESMOND) programme for people with newly diagnosed type 2 diabetes: cost effectiveness analysisBMJ, 2010
- Liraglutide versus sitagliptin for patients with type 2 diabetes who did not have adequate glycaemic control with metformin: a 26-week, randomised, parallel-group, open-label trialThe Lancet, 2010
- Efficacy and safety of incretin-based therapies: Clinical trial dataJournal of the American Pharmacists Association, 2009
- Cost-Effectiveness of Lifestyle Modification in Diabetic PatientsDiabetes Care, 2009
- Medical Management of Hyperglycemia in Type 2 Diabetes: A Consensus Algorithm for the Initiation and Adjustment of TherapyDiabetes Care, 2009
- Efficacy and Safety Comparison of Liraglutide, Glimepiride, and Placebo, All in Combination With Metformin, in Type 2 DiabetesDiabetes Care, 2009
- Cost‐effectiveness of sitagliptin‐based treatment regimens in European patients with type 2 diabetes and haemoglobin A1c above target on metformin monotherapyDiabetes, Obesity and Metabolism, 2008
- PROactive 06: cost‐effectiveness of pioglitazone in Type 2 diabetes in the UKDiabetic Medicine, 2007
- The CORE Diabetes Model: Projecting Long-term Clinical Outcomes, Costs and Costeffectiveness of Interventions in Diabetes Mellitus (Types 1 and 2) to Support Clinical and Reimbursement Decision-makingCurrent Medical Research and Opinion, 2004
- Validation of the CORE Diabetes Model Against Epidemiological and Clinical StudiesCurrent Medical Research and Opinion, 2004